Harvard Bioscience, Inc. (HBIO)
| Market Cap | 29.09M |
| Revenue (ttm) | 86.55M |
| Net Income (ttm) | -56.70M |
| Shares Out | 4.51M |
| EPS (ttm) | -12.80 |
| PE Ratio | n/a |
| Forward PE | 33.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,924 |
| Open | 6.83 |
| Previous Close | 6.83 |
| Day's Range | 6.40 - 6.83 |
| 52-Week Range | 2.81 - 9.46 |
| Beta | 1.50 |
| Analysts | Buy |
| Price Target | 18.00 (+179.07%) |
| Earnings Date | May 12, 2026 |
About HBIO
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including d... [Read more]
Financial Performance
In 2025, Harvard Bioscience's revenue was $86.55 million, a decrease of -8.06% compared to the previous year's $94.14 million. Losses were -$56.70 million, 357.1% more than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for HBIO stock is "Buy." The 12-month stock price target is $18.0, which is an increase of 179.07% from the latest price.
News
Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12...
Harvard Bioscience Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Leadership is focused on innovation and operational efficiency, targeting high-growth areas like organoids and bioproduction. Financials are strong with improved margins, reduced debt service, and new products expected to double their revenue share. Academic, pharma, and CRO markets are key segments, with Asia showing recovery.
Harvard Bioscience Earnings Call Transcript: Q4 2025
2025 saw foundational restructuring, improved margins, and a strategic pivot to translational science. Despite revenue declines from tariffs and NIH delays, cost actions drove EBITDA growth. 2026 guidance calls for modest revenue and margin gains, with NPI and Asia Pacific recovery supporting growth.
Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results
Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7% Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7% Interim CFO Mark Frost Appointed CFO on Permanent Basis Introduces Full Yea...
Harvard Bioscience Announces Reverse Stock Split
Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: H...
Harvard Bioscience Transcript: EGM 2026
Stockholders approved a reverse stock split and the option to adjourn the meeting if needed, with over 97% support for both proposals. Final results will be published in a Form 8-K within four business days.
Harvard Bioscience to Participate in KeyBanc's Virtual Healthcare Forum
HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financ...
Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET
HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on Marc...
Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas
Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA performance Expects year over year revenue growth and ...
Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth
Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant Initiative expected to deliver approximately $3 million in cost savings in 2027 ...
Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package
Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial Flexibility BroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board o...
Harvard Bioscience Earnings Call Transcript: Q3 2025
Revenue reached $20.6M with improved gross margin and adjusted EBITDA, supported by cost reductions and strong product demand. Q4 guidance anticipates $22.5–$24.5M revenue, with risks from potential NIH funding delays due to a government shutdown.
Harvard Bioscience Announces Third Quarter 2025 Financial Results
Reports Q3 2025 Revenues of $20.6M, Gross Margin of 58.4%, and Positive Cash Provided by Operations Company Expects to Refinance or Repay the Debt in the Fourth Quarter Fourth Quarter 2025 Guidance Re...
Harvard Bioscience Schedules Third Quarter 2025 Earnings Conference Call for November 6, 2025 at 8:00 AM ET
HOLLISTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2025, before the market opens on Nov...
Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States
HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a leading provider of innovative laboratory equipment, is pleased ...
Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors
HOLLISTON, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced the appointment of Stephen DeNelsky to its Board of...
Harvard Bioscience Earnings Call Transcript: Q2 2025
Q2 2025 revenue was $20.5M, above guidance but down year-over-year, with gross margin at 56.4%. Cost reductions improved adjusted EBITDA and cash flow, while macro risks from NIH funding and tariffs persist. Q3 guidance is $19–$21M revenue and 56%–58% margin.
Harvard Bioscience Announces Second Quarter 2025 Financial Results
Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by Operations Third Quarter 2025 Guidance Reflects Improved Operations and Strong Financial Discipline New Credit ...
Harvard Bioscience Schedules Second Quarter 2025 Earnings Conference Call for August 11, 2025 at 8:00 AM ET
HOLLISTON, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2025, before the market opens on August 1...
Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board
HOLLISTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced a CEO succession plan under which John Duke will ass...
Harvard Bioscience Appoints John Duke to Board of Directors
HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of John Duke to its board of directors, effective June 2, 20...
Harvard Bioscience Earnings Call Transcript: Q1 2025
Q1 2025 revenue and gross margin declined year-over-year, with a $48M goodwill impairment driving a large operating loss. Cash flow improved, and net debt was reduced. New product launches and regulatory trends support future growth, but uncertainty in NIH funding and China tariffs weigh on the outlook.
Harvard Bioscience Announces First Quarter 2025 Financial Results
HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2025.
Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET
HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, ...
Harvard Bioscience Announces CFO Transition
HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Jennifer Cote, the Company's Chief Financial Officer and...